SmithRx will offer Yusimry through Mark Cuban’s online pharmacy for $569.27, and members will be able to apply their insurance benefits.
SmithRx is working with Mark Cuban Cost Plus Drug Company to provide Yusimry (adalimumab-aqvh), offering the Humira biosimilar through the online mail-order pharmacy for $569.27 plus dispensing and shipping fees. SmithRx members will also be able to apply their insurance benefits. SmithRx will be the first PBM to provide access to the Yusimry.
Jake Frenz
“Unlike traditional PBMs, SmithRx prioritizes transparency and up-front cost savings. Humira is often an employer’s top drug expense so offering a low-cost alternative will have significant impact,” Jake Frenz, chief executive officer and founder of SmithRx, said in a press release. SmithRx works with more than 250 broker offices and serves more than 2,500 employers in the United States. Founded in 2016, SmithRx uses a per member per month (PMPM) revenue model and includes pass-through pricing to clients. SmithRx executives said plan sponsors pay what the pharmacy is paid, and receive all manufacturer rebates.
Yusimry, approved by the FDA in 2021, is a tumor necrosis factor (TNF) blocker to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, and to treat Crohn’s disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa.
Coherus will launch Yusimry in July with a list price of $995 per carton (2 autoinjectors), which represents an 85% discount off Humira list price of $6,922 per carton of two autoinjectors. Earlier this month, Cost Plus Drugs and Coherus Biosciences announced plans to offer the biosimilar. Yusimry will also be included in the Team Cuban Card (teamcubancard.com) prescription benefit program through participating pharmacies.
Amgen launched the first of the highly anticipated biosimilars Humira in January. Amgen said at the time it is making Amjevita (adalimumab-atto) available with two pricing options. The first is a 5% below the current Humira price, while the second is 55% below the current Humira list price.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More